Q3 Earnings Forecast for Alto Neuroscience Issued By Wedbush

Alto Neuroscience, Inc. (NYSE:ANRO) – Analysts at Wedbush upped their Q3 2025 EPS estimates for shares of Alto Neuroscience in a report released on Thursday, August 14th. Wedbush analyst L. Chico now expects that the company will earn ($0.69) per share for the quarter, up from their previous estimate of ($0.70). Wedbush currently has a “Neutral” rating and a $4.00 target price on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share. Wedbush also issued estimates for Alto Neuroscience’s Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($2.59) EPS, Q1 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.57) EPS and FY2026 earnings at ($2.21) EPS.

Separately, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Alto Neuroscience in a research report on Thursday, June 26th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Alto Neuroscience has a consensus rating of “Moderate Buy” and an average target price of $8.50.

Alto Neuroscience Stock Up 1.0%

Shares of NYSE ANRO opened at $3.15 on Monday. The firm’s 50-day moving average price is $2.70 and its 200-day moving average price is $2.72. The company has a current ratio of 18.43, a quick ratio of 18.43 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $85.30 million, a price-to-earnings ratio of -1.32 and a beta of 1.84. Alto Neuroscience has a 12-month low of $1.60 and a 12-month high of $15.04.

Alto Neuroscience (NYSE:ANRO) last announced its earnings results on Wednesday, August 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.08).

Institutional Trading of Alto Neuroscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bridgeway Capital Management LLC raised its position in Alto Neuroscience by 85.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock worth $119,000 after purchasing an additional 25,000 shares during the period. Jane Street Group LLC purchased a new stake in Alto Neuroscience in the 2nd quarter worth about $240,000. Armistice Capital LLC raised its position in Alto Neuroscience by 1.5% in the 2nd quarter. Armistice Capital LLC now owns 1,624,000 shares of the company’s stock worth $3,573,000 after purchasing an additional 24,000 shares during the period. Marshall Wace LLP raised its position in Alto Neuroscience by 9.9% in the 2nd quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock worth $2,062,000 after purchasing an additional 84,417 shares during the period. Finally, AlphaCore Capital LLC raised its position in Alto Neuroscience by 100.0% in the 2nd quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $44,000 after purchasing an additional 10,000 shares during the period.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.